# Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab

> **NCT04359667** · — · UNKNOWN · sponsor: **University Hospital for Infectious Diseases, Croatia** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19
- Severe Pneumonia

## Interventions

- **DRUG:** Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]

## Key facts

- **NCT ID:** NCT04359667
- **Lead sponsor:** University Hospital for Infectious Diseases, Croatia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-16
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-05-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359667, "Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04359667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*